Mycobacterium tuberculous Infection

  • Michael Glickman
Part of the Current Clinical Oncology book series (CCO)


This chapter will outline various aspects of the diagnosis and treatment of Tuberculous in the cancer patient. We provide a general framework to understand the relationship between immunosuppressive cancer therapy and TB risk. We also review information about the risk of TB with specific malignancies and their treatment. It is our intention that this chapter will provide a cancer-specific supplement the information contained in national guidelines about TB therapy.


Cancer Tuberculous Disseminated disease Cellular immune defect Immunotherapy Chemotherapy Lymohoma Solid tumors Purin analog Alemtuzumab Graft versus host disease T-cell defect 


  1. 1.
    CDC. Treatment of tuberculosis. MMWR Recomm Rep. 2003;52:1–77.Google Scholar
  2. 2.
    CDC. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep. 2000;49:1–51.Google Scholar
  3. 3.
    CDC. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep. 2000;49:1–125, CE121–127.Google Scholar
  4. 4.
    Doffinger R, Dupuis S, Picard C, Fieschi C, Feinberg J, et al. Inherited disorders of IL-12- and IFNgamma-mediated immunity: a molecular genetics update. Mol Immunol. 2002;38:903–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Al-Muhsen S, Casanova JL. The genetic heterogeneity of mendelian susceptibility to mycobacterial diseases. J Allergy Clin Immunol. 2008;122:1043–51.PubMedCrossRefGoogle Scholar
  6. 6.
    Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol. 2001;19:93–129.PubMedCrossRefGoogle Scholar
  7. 7.
    Louie E, Rice LB, Holzman RS. Tuberculosis in non-Haitian patients with acquired immunodeficiency syndrome. Chest. 1986;90:542–5.PubMedCrossRefGoogle Scholar
  8. 8.
    Vieira J, Frank E, Spira TJ, Landesman SH. Acquired immune deficiency in Haitians: opportunistic infections in previously healthy Haitian immigrants. N Engl J Med. 1983;308:125–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med. 1989;320:545–50.PubMedCrossRefGoogle Scholar
  10. 10.
    Kamboj M, Sepkowitz KA. The risk of tuberculosis in patients with cancer. Clin Infect Dis. 2006;42:1592–5.PubMedCrossRefGoogle Scholar
  11. 11.
    Feld R, Bodey GP, Groschel D. Mycobacteriosis in patients with malignant disease. Arch Intern Med. 1976;136:67–70.PubMedCrossRefGoogle Scholar
  12. 12.
    Kaplan MH, Armstrong D, Rosen P. Tuberculosis complicating neoplastic disease. A review of 201 cases. Cancer. 1974;33:850–8.PubMedCrossRefGoogle Scholar
  13. 13.
    De La Rosa GR, Jacobson KL, Rolston KV, Raad II, Kontoyiannis DP, et al. Mycobacterium tuberculosis at a comprehensive cancer centre: active disease in patients with underlying malignancy during 1990-2000. Clin Microbiol Infect. 2004;10:749–52.CrossRefGoogle Scholar
  14. 14.
    Cordonnier C, Martino R, Trabasso P, Held TK, Akan H, et al. Mycobacterial infection: a difficult and late diagnosis in stem cell transplant recipients. Clin Infect Dis. 2004;38:1229–36.PubMedCrossRefGoogle Scholar
  15. 15.
    de la Camara R, Martino R, Granados E, Rodriguez-Salvanes FJ, Rovira M, et al. Tuberculosis after hematopoietic stem cell transplantation: incidence, clinical characteristics and outcome. Spanish Group on Infectious Complications in Hematopoietic Transplantation. Bone Marrow Transplant. 2000;26:291–8.PubMedCrossRefGoogle Scholar
  16. 16.
    George B, Mathews V, Srivastava A, Chandy M. Infections among allogeneic bone marrow transplant recipients in India. Bone Marrow Transplant. 2004;33:311–5.PubMedCrossRefGoogle Scholar
  17. 17.
    Garces Ambrossi G, Jakubowski A, Feinstein MB, Weinstock DM. Active tuberculosis limited to foreign-born patients after allogeneic hematopoietic stem cell transplant. Bone Marrow Transplant. 2005;36:741–3.PubMedCrossRefGoogle Scholar
  18. 18.
    Abad S, Gyan E, Moachon L, Bouscary D, Sicard D, et al. Tuberculosis due to Mycobacterium bovis after alemtuzumab administration. Clin Infect Dis. 2003;37:e27–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Baez Y, Giron F, Nino-Murcia A, Rodriguez J, Salcedo S. Experience with Alemtuzumab (Campath-1H) as induction agent in renal transplantation followed by steroid-free immunosuppression. Transplant Proc. 2008;40:697–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Walsh R, Ortiz J, Foster P, Palma-Vargas J, Rosenblatt S, et al. Fungal and mycobacterial infections after Campath (alemtuzumab) induction for renal transplantation. Transpl Infect Dis. 2008;10:236–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Peleg AY, Husain S, Kwak EJ, Silveira FP, Ndirangu M, et al. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis. 2007;44:204–12.PubMedCrossRefGoogle Scholar
  22. 22.
    Au WY, Leung AY, Tse EW, Cheung WW, Shek TW, et al. High incidence of tuberculosis after alemtuzumab treatment in Hong Kong Chinese patients. Leuk Res. 2008;32:547–51.PubMedCrossRefGoogle Scholar
  23. 23.
    Thursky KA, Worth LJ, Seymour JF, Miles Prince H, Slavin MA. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*. Br J Haematol. 2006;132:3–12.PubMedCrossRefGoogle Scholar
  24. 24.
    Frank DA, Mahajan S, Ritz J. Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nat Med. 1999;5:444–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Samonis G, Kontoyiannis DP. Infectious complications of purine analog therapy. Curr Opin Infect Dis. 2001;14:409–13.PubMedCrossRefGoogle Scholar
  26. 26.
    Silva FA, Matos JO, de Mello QFC, Nucci M. Risk factors for and attributable mortality from tuberculosis in patients with hematologic malignances. Haematologica. 2005;90:1110–5.PubMedGoogle Scholar
  27. 27.
    Au WY, Kwong YL, Ma SK, Mak YK, Wong KF, et al. Hairy cell leukemia in Hong Kong Chinese: a 12-year retrospective survey. Hematol Oncol. 2000;18:155–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Rietschel P, Wolchok JD, Krown S, Gerst S, Jungbluth AA, et al. Phase II study of extended-dose temozolomide in patients with melanoma. J Clin Oncol. 2008;26:2299–304.PubMedCrossRefGoogle Scholar
  29. 29.
    Su YB, Sohn S, Krown SE, Livingston PO, Wolchok JD, et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol. 2004;22:610–6.PubMedCrossRefGoogle Scholar
  30. 30.
    de Paiva Jr TF, de Barros ESMJ, Rinck Jr JA, Fanelli MF, Gimenes DL. Tuberculosis in a patient on temozolomide: a case report. J Neurooncol. 2008;92:33–5.PubMedCrossRefGoogle Scholar
  31. 31.
    Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098–104.PubMedCrossRefGoogle Scholar
  32. 32.
    Levine JE, Paczesny S, Mineishi S, Braun T, Choi SW, et al. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood. 2008;111:2470–5.PubMedCrossRefGoogle Scholar
  33. 33.
    Seong SS, Choi CB, Woo JH, Bae KW, Joung CL, et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol. 2007;34:706–11.PubMedGoogle Scholar
  34. 34.
    Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 2003;48:2122–7.PubMedCrossRefGoogle Scholar
  35. 35.
    Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med. 2008;149:177–84.PubMedCrossRefGoogle Scholar
  36. 36.
    Mazurek GH, Jereb J, Lobue P, Iademarco MF, Metchock B, et al. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep. 2005;54:49–55.PubMedGoogle Scholar
  37. 37.
    Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc. 1970;26:28–106.PubMedGoogle Scholar
  38. 38.
    WHO. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ. 1982;60:555–64.Google Scholar
  39. 39.
    Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet. 1999;353:1843–7.PubMedCrossRefGoogle Scholar
  40. 40.
    CDC. Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens. MMWR Morb Mortal Wkly Rep. 2002;51:214–5.Google Scholar
  41. 41.
    Schwander S, Rusch-Gerdes S, Mateega A, Lutalo T, Tugume S, et al. A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. A single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis. Tuber Lung Dis. 1995;76:210–8.PubMedCrossRefGoogle Scholar
  42. 42.
    Gonzalez-Montaner LJ, Natal S, Yongchaiyud P, Olliaro P. Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus Rifampicin. Rifabutin Study Group. Tuber Lung Dis. 1994;75:341–7.PubMedCrossRefGoogle Scholar
  43. 43.
    American Thoracic Society, CDC, Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recomm Rep. 2003;52:1–77.Google Scholar
  44. 44.
    Libshitz HI, Pannu HK, Elting LS, Cooksley CD. Tuberculosis in cancer patients: an update. J Thorac Imaging. 1997;12:41–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Infectious Diseases DivisionMemorial Sloan Kettering Cancer CenterNew YorkUSA

Personalised recommendations